Nymox Pharmaceutical Corporation
NYMXF · OTC
12/31/2024 | 9/30/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $3 | $3 |
| Gross Profit | $0 | $0 | -$3 | -$3 |
| % Margin | – | – | – | – |
| R&D Expenses | $624 | $511 | $2,020 | $658 |
| G&A Expenses | $164 | $142 | $2,830 | $353 |
| SG&A Expenses | $164 | $142 | $2,830 | $353 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $788 | $653 | $4,850 | $1,011 |
| Operating Income | -$788 | -$653 | -$4,853 | -$1,014 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$69 | -$63 | -$458 | -$22 |
| Pre-Tax Income | -$857 | -$716 | -$5,311 | -$1,036 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$857 | -$716 | -$5,311 | -$1,036 |
| % Margin | – | – | – | – |
| EPS | -0.009 | -0.008 | -0.057 | -0.011 |
| % Growth | -18.2% | 86.4% | -407.1% | – |
| EPS Diluted | -0.009 | -0.008 | -0.057 | -0.011 |
| Weighted Avg Shares Out | 94,231 | 93,540 | 93,540 | 92,156 |
| Weighted Avg Shares Out Dil | 94,231 | 93,540 | 93,540 | 92,156 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17 | $0 | $3 | $0 |
| Interest Expense | $86 | $63 | $25 | $22 |
| Depreciation & Amortization | $0 | $0 | $11 | $3 |
| EBITDA | -$771 | -$653 | -$5,272 | -$1,011 |
| % Margin | – | – | – | – |